000 01767nam a2200421 i 4500
999 _c253574
_d253574
001 ocn953525232
003 BD
005 20171104203558.0
006 m o d f
007 cr bn||||m||||
008 160713s2016 dcu o f000 0 eng c
040 _aPUCPR
_beng
_erda
_epn
_cGPO
_dGPO
042 _apcc
043 _an-us---
049 _aBDDF
050 1 4 _aKF32
_b.E55 2016
074 _a1008-I (online)
086 0 _aY 1.1/8:114-672
099 _aY 1.1/8:114-672
110 1 _aUnited States.
_bCongress.
_bHouse.
_bCommittee on Energy and Commerce,
_eauthor.
245 1 0 _aDXM Abuse Prevention Act of 2015 :
_breport (to accompany H.R. 3250) (including cost estimate of the Congressional Budget Office).
264 1 _a[Washington, D.C.] :
_b[U.S. Government Publishing Office],
_c[2016]
300 _a1 online resource (26 pages).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aReport / 114th Congress, 2d session, House of Representatives ;
_v114-672
500 _aTitle from title screen (viewed on July 13, 2016).
500 _a"July 8, 2016."
500 _aCRDP Project record.
650 0 _aDextromethorphan
_xLaw and legislation
_zUnited States.
650 0 _aDrug abuse
_xLaw and legislation
_zUnited States.
650 0 _aPharmacy
_xLaw and legislation
_zUnited States.
655 7 _aLegislative materials.
_2lcgft
776 0 8 _iPrint version:
_aUnited States. Congress. House. Committee on Energy and Commerce.
_tDXM Abuse Prevention Act of 2015
_w(OCoLC)953798820
810 1 _aUnited States.
_bCongress.
_bHouse.
_tReport ;
_v114-672.
856 4 0 _3PDF version:
_uhttp://purl.fdlp.gov/GPO/gpo69959
856 4 0 _3Text version:
_uhttp://purl.fdlp.gov/GPO/gpo69960
942 _2sudocs
_c12